Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Ecnoglutide

A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity

Hangzhou Sciwind Biosciences Co · Phase 1/2 · Recruiting · Enrollment 126

NCT07243171

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
oral ecnoglutide dose 1n/rn/rn/rn/r
oral ecnoglutide dose 2n/rn/rn/rn/r
oral ecnoglutide dose 3n/rn/rn/rn/r
oral ecnoglutide dose 4n/rn/rn/rn/r
placebo dose 1n/rn/rn/rn/r
placebo dose 2n/rn/rn/rn/r

Not shown

  • oral ecnoglutide dose 1: endpoint not reported
  • oral ecnoglutide dose 2: endpoint not reported
  • oral ecnoglutide dose 3: endpoint not reported
  • oral ecnoglutide dose 4: endpoint not reported
  • placebo dose 1: endpoint not reported
  • placebo dose 2: endpoint not reported